Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer

YAN Yuting# , SUN Jieyu# , LI Qian

PDF(4116 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(4116 KB)
World Clinical Drug ›› 2024, Vol. 45 ›› Issue (3) : 317-323. DOI: 10.13683/j.wph.2024.03.013
Topic

Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2024, 45(3): 317-323 https://doi.org/10.13683/j.wph.2024.03.013

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(4116 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉